# US 2005/0032804 A1 · Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032804 A1
- Document ID: US20050032804A1
- Status: Published application
- Kind: A1
- Application number: 10/874,992
- Filed: 2004-06-23
- Published: 2005-02-10
- Earliest claimed: 2003-06-24
- Assignees: Merck & Co., Inc.
- Inventors: Stephen Cypes; Alex Chen; Russell Ferlita; Karl Hansen; Ivan Lee; Vicky Vydra; Robert Wenslow
- Web page: https://patentgrep.com/patent/US20050032804A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/12: Antihypertensives
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

## Claims

### Claim 1

A dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural formula I:
or a pharmaceutically acceptable hydrate thereof.

### Claim 2 (depends on 1)

The salt of claim 1 of structural formula II having the (R)-configuration at the chiral center marked with an *

### Claim 3 (depends on 1)

The salt of claim 1 of structural formula III having the (S)-configuration at the chiral center marked with an *

### Claim 4 (depends on 2)

The salt of claim 2 characterized in being a crystalline monohydrate.

### Claim 5 (depends on 4)

The monohydrate of claim 4 characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.42, 5.48, and 3.96 angstroms.

### Claim 6 (depends on 5)

The monohydrate of claim 5 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 6.30, 4.75, and 4.48 angstroms.

### Claim 7 (depends on 6)

The monohydrate of claim 6 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 5.85, 5.21, and 3.52 angstroms.

### Claim 8 (depends on 7)

The monohydrate of claim 7 further characterized by the X-ray powder diffraction pattern of FIG. 1.

### Claim 9 (depends on 4)

The monohydrate of claim 4 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 169.1, 120.8, and 46.5 ppm.

### Claim 10 (depends on 9)

The monohydrate of claim 9 further characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 159.0, 150.9, and 40.7 ppm.

### Claim 11 (depends on 10)

The monohydrate of claim 10 further characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 2.

### Claim 12 (depends on 4)

The monohydrate of claim 4 characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at −64.5, −114.7, −136.3, and −146.2 ppm.

### Claim 13 (depends on 12)

The monohydrate of claim 12 further characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at −96.5, −104.4, −106.3, and −154.5 ppm.

### Claim 14 (depends on 13)

The monohydrate of claim 13 further characterized by the solid-state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 3.

### Claim 15 (depends on 4)

The monohydrate of claim 4 characterized by the thermogravimetric analysis curve of FIG. 4.

### Claim 16 (depends on 4)

The monohydrate of claim 4 characterized by the differential scanning calorimetric curve of FIG. 5.

### Claim 17 (depends on 4)

The salt of claim 4 comprising a detectable amount of said crystalline monohydrate.

### Claim 18 (depends on 4)

The salt of claim 4 comprising about 5% to about 100% by weight of said crystalline monohydrate.

### Claim 19 (depends on 4)

The salt of claim 4 comprising about 10% to about 100% by weight of said crystalline monohydrate.

### Claim 20 (depends on 4)

The salt of claim 4 comprising about 25% to about 100% by weight of said crystalline monohydrate.

### Claim 21 (depends on 4)

The salt of claim 4 comprising about 50% to about 100% by weight of said crystalline monohydrate.

### Claim 22 (depends on 4)

The salt of claim 4 comprising about 75% to about 100% by weight of said crystalline monohydrate.

### Claim 23 (depends on 4)

The salt of claim 4 comprising substantially all by weight of said crystalline monohydrate.

### Claim 24

A salt comprising the ions of monoprotonated 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine cation and dihydrogenphosphate anion.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the salt according to claim 1 or a pharmaceutically acceptable solvate thereof in association with one or more pharmaceutically acceptable carriers.

### Claim 26 (depends on 4)

A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the salt according to claim 4 or a pharmaceutically acceptable solvate thereof in association with one or more pharmaceutically acceptable carriers.

### Claim 27 (depends on 1)

A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 1 or a pharmaceutically acceptable hydrate thereof.

### Claim 28 (depends on 4)

A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 4.

### Claim 29 (depends on 1)

A process for preparing the salt of claim 1 comprising the step of contacting one equivalent of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine in an organic solvent or aqueous organic solvent with about a one equivalent of phosphoric acid at a temperature in the range of about 25-100° C.

### Claim 30 (depends on 29)

The process of claim 29 wherein said organic solvent is a C1-C5 linear or branched alkanol.

### Claim 31 (depends on 1)

Use of the salt of claim 1 as active ingredient in the manufacture of a medicament for use in the treatment of type 2 diabetes.

### Claim 32 (depends on 4)

Use of the salt of claim 4 as active ingredient in the manufacture of a medicament for use in the treatment of type 2 diabetes.

### Claim 33 (depends on 25)

The pharmaceutical composition of claim 25 adapted for i.v. administration.

### Claim 34 (depends on 29)

The phosphoric acid salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine prepared according to the process of claim 29.

### Claim 35 (depends on 1, 4)

A process for preparing the crystalline monohydrate of claim 4 comprising the steps of:
(a) crystallizing said dihydrogenphosphate salt of claim 1 at 25° C. from a mixture of isopropanol and water, such that the water concentration is above 6.8 weight percent;
(b) recovering the resultant solid phase; and
(c) removing the solvent therefrom.
